Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval The agency has recently signaled it’s more open to considering rare disease treatments after a staff shakeup

https://www.statnews.com/2026/06/24/regenxbio-duchenne-gene-therapy-fda-submission/ By Jason MastJune 24, 2026 General Assignment Reporter